S1052 A Nationwide Comparison of Ustekinumab, Vedolizumab, and Adalimumab on Infections, Vascular Disorders, and Neuromusculoskeletal Adverse Events in Ulcerative Colitis Patients: A Pharmacovigilance Investigation

医学 维多利祖马布 乌斯特基努马 阿达木单抗 不良事件报告系统 溃疡性结肠炎 不利影响 内科学 优势比 炎症性肠病 疾病
作者
Clive J. Miranda,Yash P. Ashara,Ruchir Paladiya,Gregory D. Gudleski,Bhavtosh Dedania
出处
期刊:The American Journal of Gastroenterology [American College of Gastroenterology]
卷期号:118 (10S): S800-S800
标识
DOI:10.14309/01.ajg.0000953848.50788.0d
摘要

Introduction: Biologic drugs have played a key role in the effective induction and maintenance of disease remission in ulcerative colitis (UC). With subclasses ranging from anti-tumor necrosis factor agents to anti-integrins and anti-IL12/23 therapies, biologics have revolutionized pharmacological management of UC since the early 2000s. These therapies have variable safety profiles with several side-effects being reported in UC patients on these medications. In a nationwide cohort of UC patients here, we stratify the safety profiles of the biologic agents ustekinumab, vedolizumab, and adalimumab. Methods: The US Food and Drug Administration’s Adverse Event Reports System (FAERS) was queried for ustekinumab, vedolizumab and adalimumab in CD on February 5, 2023, which was updated on January 30, 2023. Patient demographics were recorded as well as rates of infection, vascular reactions, and neuromusculoskeletal adverse events whilst on these drugs. Analysis was performed using reported odds ratios (ROR) with 95% confidence interval (CI) and statistical significance P < 0.05. Results: A dataset of 34,418 reported adverse event cases of UC patients treated with ustekinumab, vedolizumab, and adalimumab until December 31, 2022, was extracted from the FAERS database. 15,404 (44.8%) patients were male. Patients with UC were significantly more likely to contract an infection whilst on ustekinumab than those on adalimumab [RR 1.20, 95% CI 1.06-1.35, P < 0.05]. The same was true for vedolizumab [RR 1.22, 95% CI 1.16-1.28, P < 0.001]. There were significant reductions in vascular complications [RR 0.51, 95% CI 0.35-0.74, P < 0.001] and musculoskeletal complications [RR 0.52, 95% CI 0.41-0.65, P < 0.001] in patient being treated with ustekinumab than those on adalimumab. Nervous system adverse complications were significantly reduced for ustekinumab (RR 0.76, 95% CI 0.63-0.91, P < 0.001) and vedolizumab (RR 0.83, 95% CI 0.78-0.89, P < 0.001) when compared to adalimumab. From the reported events, the rate of hospitalization of UC patients on ustekinumab, vedolizumab and adalimumab were 21%, 31% and 23% respectively. Incorporating gender and age did not yield any statistical significance. Conclusion: Patients with UC on ustekinumab as well as those on vedolizumab both had significantly higher rates of infection than patients with UC on adalimumab. Interestingly, UC patients on ustekinumab had significantly lower rates of vascular and musculoskeletal complications than patients on adalimumab (see Figure 1).Figure 1.: Forest plot of adverse reactions with ustekinumab (U) and vedolizumab (V) with respect to adalimumab in ulcerative colitis patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lll完成签到,获得积分10
刚刚
菜籽发布了新的文献求助10
1秒前
Hello应助18746005898采纳,获得10
2秒前
4秒前
隐形曼青应助等待冰露采纳,获得10
5秒前
慕青应助liuweiwei采纳,获得10
6秒前
我是老大应助Raye采纳,获得10
6秒前
Hello应助Edsorn采纳,获得10
6秒前
打打应助ocean采纳,获得10
6秒前
8秒前
10秒前
yu完成签到,获得积分20
11秒前
迅速斑马发布了新的文献求助10
11秒前
爆米花应助wwnd采纳,获得10
11秒前
丘比特应助JJJJJJJ采纳,获得10
12秒前
冰柠橙夏关注了科研通微信公众号
12秒前
YY发布了新的文献求助10
12秒前
13秒前
TimelyRain发布了新的文献求助10
13秒前
clean发布了新的文献求助20
13秒前
科研通AI2S应助沧海君采纳,获得10
15秒前
汉堡包应助小范同学采纳,获得10
15秒前
luyao970131发布了新的文献求助10
16秒前
鸡腿子完成签到,获得积分10
16秒前
17秒前
某某完成签到,获得积分10
17秒前
17秒前
18秒前
bzlish完成签到,获得积分20
18秒前
刻苦以寒完成签到,获得积分10
19秒前
起风了发布了新的文献求助10
20秒前
Mars夜愿发布了新的文献求助10
20秒前
CodeCraft应助调皮的凝旋采纳,获得10
21秒前
迅速斑马完成签到,获得积分10
21秒前
李爱国应助活泼糜采纳,获得10
22秒前
认真读文献应助黄花采纳,获得10
22秒前
科目三应助hyf采纳,获得10
23秒前
bzlish发布了新的文献求助10
23秒前
24完成签到,获得积分10
24秒前
kk关注了科研通微信公众号
24秒前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3051374
求助须知:如何正确求助?哪些是违规求助? 2708662
关于积分的说明 7413751
捐赠科研通 2352869
什么是DOI,文献DOI怎么找? 1245378
科研通“疑难数据库(出版商)”最低求助积分说明 605633
版权声明 595829